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 Abstract    
Objective: Idiopathic hirsutism (IH) or polycystic ovary syndrome (PCOS) are the most common causes of hirsu-
tism which affects 5–10 % of all women. The aim of this study was to evaluate the efficacy of flutamide plus diane 
35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
Materials and Methods: 26 polycystic ovary syndrome and 24 idiopathic hirsutism patients were evaluated. 
Fifty patients were divided into two groups according to their diagnosis:  idiopathic hirsutism or polycystic ovary 
syndrome. All patients received 125mg Flutamide once a day and Diane 35 tablets for 21 days of each month, 
for 12 months. We measured hirsutism scores and hormonal levels of all patients. Evaluations were done before 
treatment, in the 6th and 12th months of therapy.
Results: There were no significant differences in Ferriman-Gallwey scores at the beginning and at the end of the 
therapy between the IH and PCOS groups. The decreases in Ferriman-Gallwey scores were significant in both gro-
ups in the 6th and 12th month of therapy. Combined treatment significantly decreased total and free testosterone, 
DHEAS and significantly increased SHBG levels in both groups and additionally decreased levels of LH, androste-
nodione and LH/FSH ratio in the polycystic ovary syndrome group.
Conclusion: Combined treatment was effective and safe in the treatment of hirsutism. Combined regimens have 
additional effects on the treatment of hirsutism. 
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Introduction
Hirsutism	is	a	disorder	which	becomes	present	with	a	male	
type	hair	and	male	type	distribution	that	may	be	the	consequence	
of	either	androgen	excess	or	increased	sensitivity	of	hair	follicles	
to	 normal	 levels	 of	 androgens.1	 Idiopathic	 hirsutism	 (IH)	 or	
polycystic	ovary	syndrome	(PCOS)	are	the	most	common	causes	
of	hirsutism	which	affects	5–10	%	of	all	women.	Both	of	them	are	
very	distressing	conditions	for	women.2	Mechanical	hair	removal	
is	 an	 effective	way	 of	 treatment	 among	many	 hirsute	women.	
However,	 pharmacological	 approach	 is	 usually	 required	 in	
patients	with	moderate	to	severe	hirsutism	to	suppress	androgen	
production	and/or	action.	
Flutamide	 is	 an	 effective	 drug	 for	 women	 with	 IH	 or	
PCOS.	This	drug	is	a	pure	peripheral	androgen	antagonist	with	
no	 progestogenic	 or	 antigonadotropic	 action	 and	 reduces	 the	
synthesis	 of	 androgens	 or	 increases	 their	 metabolism.3 Some 
of	the	researchers	described	a	relationship	between	amenorrhea	
and	flutamide	used	during	the	treatment	of	hirsutism.4	However, 
flutamide	has	non-steroidal	shape	therefore	it	is	reasonable	not	to	
expect	menstrual	irregularity.5 
Cyproterone	 acetate	 (CPA)	 is	 a	 17-hydroxyprogesterone	
acetate	 derivative	 that	 competes	 with	 dihydrotestosterone 
(DHT)	 for	 the	 androgen	 receptor	 and	 reduces	 LH	 levels	
which	 decrease	 testosterone	 and	 androstenedione	 levels.5 
CPA	 has	 antiandrogenic	 and	 antigonadotropic	 activity	 and	 is	
ideal	 for	 hyperandrogenichirsutism.6	 Combination	 with	 CPA/
ethinyloestradiol(EE)	 can	 help	 ensure	 an	 adequate	 estrogen	
input	and	allow	regular	bleeding.7	Combined	oral	contraceptives	
(COCs)	are	an	accepted	first	step	traditional	treatment	modality	
of	 hirsutism	 and	 they	 effectively	 suppress	 ovarian	 androgen	
production.8	Their	progestational	activity	reduces	LH	secretion	
and	 lowers	 the	 release	 of	 LH-mediated	 ovarian	 androgen.	
Estrogenic	component	of	COCs	increases	sex	hormone-binding	
globulin	(SHBG)	which	decreases	the	amount	of	free	testosterone	
(FT).9
The	Diane-35®	(Bayer	[South	East	Asia]	Pte	Ltd,	Singapore)	
is	 a	combination	of	CPA	and	EE.	The	objective	of	 the	present	
study	was	to	evaluate	the	efficacy	of	125mg	flutamide	(Eulexin,	
Schering)	plus	Diane-35	in	the	treatment	of	hirsutism.	
Material and methods
Fifty	 hirsute	 female	 patients	 of	 our	 reproductive	
endocrinology	 clinic	 were	 enrolled	 in	 the	 study.	 Hirsutism	
evaluation	was	measured	using	the	modified	Ferriman–	Gallwey	
(mFG)	 scoring	 method	 described	 by	 Hatch	 et	 al.10	All	 scores	
were	measured	by	the	same	specialist	and	after	the	examination	
the	 patients	 were	 divided	 into	 two	 groups,	 according	 to	 their	
diagnosis,	IH	or	PCOS.	The	study	was	approved	by	the	Ethical	
Committee	of	Erciyes	University.	Written	informed	consent	was	
obtained	from	all	the	participants	at	the	ages	between	16	and	43.	
None	of	the	patients	had	history	of	hypertension,	thromboembolic	
disease,	 diabetes	 mellitus,	 cardiovascular	 events,	 or	 received	
treatment	with	COCs,	antiandrogens	or	insulin	sensitizers	for	6	
months	prior	to	the	study.
Of	 the	 50	 patients,	 26	 (52%)	were	 diagnosed	with	 PCOS	
and	 24	 (48%)	 with	 IH.	 We	 proposed	 that	 a	 diagnosis	 of	 IH	
should	 only	 be	 made	 in	 hirsute	 patients	 who	 have	 normal	
androgen	levels	and	regular	ovulatory	menstrual	cycles.11-12 The 
diagnosis	of	PCOS	was	made	according	to	the	Rotterdam	PCOS	
Consensus.13	 Ultrasonographic	 diagnosis	 of	 polycystic	 ovaries	
was	based	on	the	presence	of	12	or	more	follicles	in	each	ovary	
measuring	2–9	mm	in	diameter,	and/or	increased	ovarian	volume	
>10	 ml	 on	 pelvic	 or	 vaginal	 ultrasound	 examination.14	 Oligo/
amenorrhea	were	defined	as	the	absence	of	menstruation	for	35	
days	or	more.15 
All	 patients	 received	 125mg	 flutamide	 once	 a	 day	 and	
Diane	35,	for	21	days	of	each	month	in	the	course	of	12	months.	
The	therapy	was	started	on	the	first	day	of	the	menstrual	cycle.	
Blood	samples	were	taken	during	the	mid-follicular	phase	of	the	
menstrual	cycle.	Hormonal	analyses	included	FSH,	LH,	SHBG,	
17alpha-hydroxyprogesterone	 (17-OHP),	 E2,	 androstenedione,	
total	testosterone	(TT),	FT,	PRL	and	DHEAS.	
Clinical	 side	 effects	were	 assessed	monthly	 by	 examining	
a	 range	 of	 biochemical	 parameters.	 Patient	 complaints,	 i.e.	
potential	side	effects,	were	recorded	each	month.	Hormonal	tests	
and	hirsutism	scores	(HS)	were	evaluated	in	6th	and	12th	month	
of	 the	 therapy.	After	centrifugation,	blood	serum	was	stored	at	
–20°C	until	assayed.	Serum	TT,	FT,	androstenedione,	DHEAS,	
FSH,	LH,	E2	and	17-OHP	were	measured	by	radioimmunoassay	
 Streszczenie 
Cel: Idiopatyczny hirsutyzm (IH) oraz zespół policystycznych jajników (PCOS) są najczęstszymi przyczynami hi-
rsutyzmu, który dotyka 5-10% wszystkich kobiet. Celem pracy była ocena skuteczności flutamidu i Diane 35 w 
leczeniu idiopatycznego hirsutyzmu i zespołu policystycznych jajników.
Materiał i metoda: Zbadano 26 kobiet z zepołem PCO i 24 z idiopatycznym hirsutyzmem. Stanowiły one dwie 
grupy badane. Wszystkie pacjentki otrzymały 125mg flutamidu raz dziennie i Diane-35 przez 21 dni. Leczenie trwa-
ło 12 miesięcy. Zmierzono nasilenie hirsutyzmu i poziom hormonów u badanych pacjentek przed leczeniem oraz 
po 6 i 12 miesiącach terapii.
Wyniki: Nie znaleziono istotnych różnic w skali Ferrimana-Gallwaya na początku i na końcu leczenia pomiędzy 
grupą z IH a grupą PCOS. Zmniejszenie nasilenia hirsutyzmu wg skali Ferrimana-Gallwaya było istotne w obu 
grupach w 6 i 12 miesiącu terapii. Skojarzone leczenie istotnie zmniejszało całkowity i wolny testosteron, DHEAS i 
istotnie zwiększało poziom SHBG w obu grupach badanych. Dodatkowo zmniejszało poziom LH, androstendionu i 
stosunek LH/FSH w grupie z policystycznymi jajnikami.
Wnioski: Skojarzone leczenie hirsutyzmu jest skuteczne i bezpieczne. Skojarzone dawki mają sumarycznie więk-
szy wpływ na lecznie hirsutyzmu. 
 Słowa kluczowe: hirsutyzm / flutamid / Diane-35 /
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using	 commercial	 kits	 (DPC,	 Los	Angeles,	 Ca,	 USA).	 SHBG	
was	measured	by	immunoradiometric	assay	(Orion	Diagnostica,	
Espo,	Finland).	The	intra-	and	inter-assay	precision	coefficients	
of	 the	variation	were	3.2%	and	4.4%	for	FSH,	6.8%	and	7.9%	
for	LH,	5.2%	and	5.5%	for	E2,	10%	and	10.4%	for	testosterone,	
4.3%	and	5.5%	for	FT,	8.3%	and	9.2%	for	androstenedione,	39%	
and	7.0%	for	DHEAS,	5.6%	and	4.5%	for	17-OHP,	and	4.0%	and	
5.5%	for	SHBG	respectively.	All	results	are	given	as	means	±	sd.
Statistics
All	 continuous	 variables	 were	 reported	 as	 mean±standard	
deviation.	Changes	in	the	serum	hormone	levels	among	baseline	
and	 6th	 and	 12th	 month	 of	 therapy	 with	 PCOS	 and	 IH	 were	
analyzed	by	two	way	analysis	of	variance	for	repeated	measures.	
The	adjustment	for	multiple	comparisons	was	performed	with	the	
Bonferroni	correction.	Independent	proportions	between	groups	
were	 compared	 with	 the	 chi-square	 test.	 Differences	 between	
the	 groups	were	 evaluated	 using	 an	 unpaired	 t	 test.	A	 p	 value	
of	<0.05	was	regarded	as	statistically	significant.	Analysis	was	
performed	with	 the	Statistical	Package	 for	 the	Social	Sciences	
version	15.0	(SPSS	Inc,	Chicago,	IL,	USA).
Results 
The	 baseline	 characteristics	 of	 the	 two	 treatment	 groups	
were	 similar.	 The	mean	 age	 of	 the	 PCOS	 and	 IH	 groups	was	
25.23±7.27	and	25.17±6.95	years,	respectively	(p>0.05).	Normal	
values	for	the	FG	score	are	less	than	8,	so	the	degree	of	hirsutism	
in	both	groups	was	considerable.	The	mean	value	of	mFG	score	
was	 21.85±5.96	 in	 the	PCOS	group	 and	 19.88±4.85	 in	 the	 IH	
group	 (p>0.05).	The	mean	value	 of	BMI	 in	 the	 IH	group	was	
generally	 normal	 (mean	 BMI,	 23.67).	 Although	 the	 PCOS	
group	 was	 slightly	 overweight	 (mean	 BMI,	 25.50),	 there	 was	
no	 statistically	 significant	 difference	 between	 the	 two	 groups	
(p>0.05).	Oligo/amenorrhea	was	 detected	 in	 21	 of	 26	 patients	
in	 the	PCOS	group	and,	naturally,	we	did	not	detect	menstrual	
irregularity	 in	 the	 IH	 group.	 At	 the	 end	 of	 the	 treatment	 no	
menstrual	irregularity	was	detected	in	either	group.	Overall,	both	
drugs	were	 found	 to	 be	well-tolerated.	No	 serious	 side	 effects	
were	detected	in	the	patients.	
Table	2	 shows	 the	hormone	 levels	 and	HS	during	 therapy	
in	the	PCOS	and	IH	groups.	The	HS	before	treatment,	in	the	6th	
and	12th	month	of	the	treatment	were	similar	in	both	groups.	In	
the	group	IH	the	percent	reduction	in	HS	was	42.8±12.5%	and	
64.3±11.4%	in	the	6th	and	12th month	of	the	therapy,	respectively.	
In	the	PCOS	group	it	was	37,6±17&	and	64,8±13,8%	in	the	6th	
and	12th	month	of	the	therapy.	The	percent	reduction	in	HS	was	
not	different	between	the	IH	and	PCOS	groups	(p>0.05).		
Basal	 hormonal	 measurement	 shows	 that	 LH,	 TT,	 FT,	
androstenedione	and	LH/FSH	levels	were	significantly	elevated	
in	the	PCOS	group	(P<0.05)	There	were	no	significant	differences	
in	 all	 hormone	 levels	 and	 LH/FSH	 level	 between	 the	 6th	 and	
12th	month	of	therapy	in	both	groups;	only	SHBG	levels	showed	
statistically	significant	increase	in	the	PCOS	group.
Flutamide	 plus	 CPA/EE	 treatment	 significantly	 decreased	
TT,	 FT,	DHEAS,	 androstenedione,	 LH	 and	LH/FSH	 ratio	 and	
significantly	 increased	SHBG	levels	after	 the	first	6	months	of	
treatment	in	the	PCOS	group.	We	detected	significant	decrease	of	
TT,	FT,	DHEAS,	FSH,	OHP	and	increased	levels	of	SHBG	but	
there	were	no	statistically	significant	results	for	LH	and	LH/FSH	
ratio	 in	 the	IH	group.	Comparison	of	basal	and	end	of	 therapy	
showed	statistically	significant	decrease	of	TT,	FT	and	DHEAS	
and	 increased	 SHBG	 levels	 in	 both	 groups.	 Additionally,	
decreased	 levels	 of	 LH,	 androstenedione	 and	 LH/FSH	 ratio	
were	found	in	the	PCOS	group.	All	binary	comparisons	for	HS	
and	hormonal	 levels	 in	 the	 time	periods	 (6th	 and	12th	month)	
revealed	no	 statistically	 significant	 differences	 between	 the	 IH	
and	PCOS	groups.	
Discussion
Hirsutism	 is	 a	 common	 clinical	 condition	 in	 women	 and	
is	 characterized	 by	 excessive	 growth	 of	 terminal	 hair	 in	 the	
androgen	 sensitive	 skin	 regions.	 This	 study	 has	 shown	 that	
flutamide	plus	CPA/EE	have	an	additional,	beneficial	effect	on	
women	with	hirsutism.
Some	 authors	 suggest	 that	 flutamide	 reduces	 androgen	
synthesis	by	restoring	ovulation,	although	a	direct	block	of	the	
steroidogenic	 enzymes	 of	 androgen	 biosynthesis	 in	 ovarian	
thecal	 cells	 cannot	 be	 excluded.16	 Flutamide	 treatment	 has	
been	reported	not	to	affect	gonadotropins,	E2,	and	P	levels	and,	
therefore,	does	not	alter	 the	mechanism	of	ovulation.6	Because	
of	 peripheral	 antiandrogenic	 effect,	 flutamide	 has	 a	 potential	
risk	of	 feminization	on	a	male	 fetus	which	 requires	 the	use	of	
a	contraceptive	method	during	flutamide	treatment	of	hirsutism.	
Thus,	 a	 combined	 treatment	may	 be	 a	 good	 choice	 in	women	
with	hirsutism.17 
Flutamide	 treatment	 can	 be	 complicated	 by	 skin	 dryness,	
gastrointestinal	discomfort,	breast	tenderness	and	hepatotoxicity.	
The	reported	incidence	of	these	side	effects	increases	with	higher	
doses.	When	long-term	treatment	is	introduced,	it	is	worth	noting	
that	the	use	of	a	low	dose	reduces	both	the	cost	of	the	treatment	
and	the	possible	side	effects.18	In	terms	of	dosage	the	efficacy	of	
low-dose	flutamide	 therapy	on	hirsutism	has	 been	observed	 to	
be	similar	to	that	of	higher	daily	doses.19	In	our	study	low-dose	
flutamide	was	administered	at	a	low-dose.
COCs	have	been	established	to	reduce	circulating	androgen	
levels	 through	 the	 suppression	 of	 circulating	 LH	 and	 the	
stimulation	of	SHBG	levels.20	The	former	mechanism	is	common	
to	all	COCs	and	reflects	 the	progestin	mediated	suppression	of	
gonadotropin	 release	 and	 subsequent	 reduction	 of	 the	 ovarian	
androgen	 synthesis.	 CPA/EE	 has	 previously	 been	 reported	 to	
significantly	 decrease	 TT,	 FT,	 androstenedione,	 DHEAS,	 and	
DHT	levels	and	to	increase	SHBG	levels	in	hirsute	women.21
Calaf	et	al.,	claimed	that	flutamide	plus	COCs	reduced	HS	
by	 52.7%	 after	 12	 months	 of	 daily	 treatment.	 Our	 reduction	
is	even	higher	 than	 that	obtained	by	Calaf	et	al.,	what	may	be	
linked	with	 the	 fact	 that	 they	used	 triphasic	OC	 in	 their	 study.	
Additionally,	 all	 subjects	 in	 their	 study	 were	 premenopausal	
and	Calaf	 et	 al.,	 did	 not	 administer	CPA	 to	 the	 patients.	They	
Table I. Baseline characteristics of groups.
Variable Group (IH ) Group (PCOS) p
BMI 23.67±3.11 25.50±4.60 0.108
Age 25.17±6.95 25.23±7.27 0.980
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measured	a	standard	hormonal	profile,	including	serum	levels	of	
PRL,	 E2,	 FT,	DHEAS,	 androstenedione,	 17-OHP,	 SHBG,	TT,	
LH,	 and	 FSH,	 and	 found	 that	 flutamide	 plus	 COCs	 increased	
SHBG	and	decreased	all	of	the	hormones,	except	for	prolactin.22
CPA	 is	 an	 anti-androgen	 with	 progestational	 activity,	
currently	used	for	treating	hirsutism.	CPA	inhibits	gonadotropin	
secretion	and	competes	with	DHT	for	binding	 to	 the	androgen	
receptor.	 Diane	 plus	 flutamide	 therapy	 enabled	 us	 to	 decrease	
androgen	 levels	 of	 both	 glandular	 and	 peripheral	 origins,	 and	
interfere	 with	 the	 interaction	 of	 dihydrotestosterone	 and	 its	
intracellular	 receptor.	We	 believe	 that	 the	 combination	 of	 the	
two	drugs	may	occupy	more	receptors	than	the	one	drug	alone	
occupies.			
In	the	light	of	the	results	of	our	study	it	seems	safe	to	conclude	
that	 flutamide	 plus	Diane35	 regimen	 has	 additional,	 beneficial	
effects	 on	 the	 treatment	 of	 hirsutism	 and	 the	 contraceptive	
treatment	 helps	 to	 regulate	 menstruation,	 especially	 of	 PCOS	
patients.	Menstrual	regulation	improves	patient	satisfaction	and	
helps	 them	 take	 their	medicines	 regularly.	However,	 flutamide	
has	a	potential	risk	of	feminization	on	a	male	fetus	so	combining	
the	therapy	with	a	contraceptive	treatment	may	be	a	good	choice	
in	women	with	hirsutism.	
Table II. Hormonal levels and hirsutizm scores before and during treatment in IH (n = 24) and PCOS (n = 26).
Level at indicated month of treatment
F p* p† p‡
Baseline 6 months 12 months
HS
IH
PCOS
19.88 ± 4.85a
21.85 ± 5.96a
11.54 ± 4.17b
13.81 ± 5.61b
7.00 ± 2.59c
7.85 ± 3.86c 377.65 <0.001 0.319 0.162
TSH
IH
PCOS
1.56 ± 0.84a
1.75 ± 0.84ab
1.32 ± 0.79ab
1.58 ± 0.63ab
1.28 ± 0.79b
1.61 ± 0.78ab 3.38 0.038 0.738 0.192
PRL
IH
COS
12.86 ± 7.25
13.89 ± 7.67
10.90 ± 5.32
12.85 ± 4.69
10.96 ± 3.97
12.24 ± 5.27 2.64 0.076 0.850 0.298
FSH
IH
PCOS
7.00 ± 2.58a
6.29 ± 2.32ab
6.00 ± 1.78b
5.61 ± 1.93ab
5.74 ± 2.03b
5.86 ± 1.84ab 5.69
0.005 0.354 0.513
LH
IH
PCOS
5.33 ± 2.01a
9.18 ± 3.93b
4.89 ± 1.34a
5.09 ± 1.72a
4.43 ± 1.93a
4.70 ± 1.30a 28.52 <0.001 <0.001 <0.001
E2
IH
PCOS
57.64 ± 34.50
53.53 ± 36.62
51.51 ± 26.90
43.31 ± 21.26
47.28 ± 26.56
46.58 ± 23.09 2.83 0.064 0.657 0.514
OHP
IH
PCOS
1.20 ± 1.16a
0.87 ± 0.65ab
0.91 ± 0.76b
0.75 ± 0.36ab
0.96 ± 0.88ab
0.72 ± 0.43ab 3.18 0.046 0.630 0.193
SHB
IH
PCOS
64.50 ± 36.84a
64.17 ± 32.68a
88.23 ± 47.25b
80.84 ± 39.92b
99.06 ± 55.48bc
100.37 ± 47.97c 30.10 <0.001 0.601 0.850
DHE
IH
PCOS
2386.53 ± 1075.25a
2430.77 ± 944.09a
2008.62 ± 971.89b
1972.77 ± 727.01b
1914.33 ± 782.60b
1792.81 ± 684.69b 25.36 <0.001 0.596 0.870
AND
IH
PCOS
2.80 ± 1.67a
3.61 ± 1.69b
2.55 ± 1.14a
2.76 ± 1.12a
2.43 ± 1.20a
2.83 ± 1.26a 8.84 <0.001 0.148 0.173
TT
IH
PCOS
67.57 ± 25.10a
96.17 ± 38.05c
52.94 ± 23.61b
64.49 ± 20.29b
51.08 ± 23.79b
56.85 ± 25.02b 35.49 <0.001 0.005 0.020
ST
IH
PCOS
2.04 ± 0.93a
2.79 ± 1.06c
1.45 ± 0.66b
1.78 ± 0.64b
1.32 ± 0.57b
1.59 ± 0.55b 42.65 <0.001 0.070 0.011
LHFSH
IH
PCOS
0.78 ± 0.32a
1.55 ± 0.56b
0.97 ± 0.80a
1.02 ± 0.51a
1.09 ± 1.10a
0.88 ± 0.37a 1.48 0.233 <0.001 0.132
IH, idiopathic hirsutism; PCOS, polycystic ovary syndrome; HS, hirsutizm score; TSH, thyroid stimulating hormone; PRL, prolactin; FSH, follicle stimulating hormone; LH, 
luteinizing hormone; E2, estradiol; OHP, 17a-hydroxyprogesterone; SHB,sex hormone-binding globulin; DHE, dehydroepiandrosterone sulfate ; AND, androstenedione; TT, 
total testosterone; FT, free testosterone; LHFSH, … ; data expressed as mean+standard error; analysis was carried out by two-way analysis of variance for repeated measures, 
groups with different superscript letters were found to have statistically significant differences; *test of within-subjects effects; †interaction between both regimens; ‡test of 
between-subjects effects.
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